Apr 25, 2013, 08.10 AM | Source: CNBC-TV18
VK Sharma, fundamental analyst, HDFC Securities, recommends buying IDBI Bank and Ranbaxy Laboratories.
VK Sharma (more)
Head Private Broking & Wealth Management, | Capital Expertise: F&O
Here is the edited transcript of his discussion with CNBC-TV-18
On IDBI Bank
It has seen a decent buildup of open interest of around 8 percent. In terms of price also, the stock went up by 2-2.5 percent. At Rs 86.50 it is well placed and the next resistance comes at around Rs 90. So considering the fact that 85 Call was the level at around Rs 2.2, one can buy that with a stop loss of Rs 1. Even if the stock touches the price of Rs 90, the target price of Rs 5 in the 85 Call would be achieved.
The stock has made a recent 9-week high. It closed at around Rs 456. The price went up by something like 2.5 percent. Even if one were to buy the 460 Call at around Rs 5.5 and keep a stop loss at Rs 2 it would be possible to earn a premium of Rs 7 on this. So the Call that one is buying at Rs 5.5, it would be possible to sell it around Rs 12 in a day or two itself.
IDBI Bank to raise $500 mn via bonds
AT-1 bonds, which qualify as core or equity capita
IDBI Q3 loss @ Rs 2184cr on high provisions, slippages up 4-fold
In absolute terms, gross NPA jumped 33 percent qua
IDBI Bank raises Rs 1,000 cr from bonds to fund infra projects
IDBI Omni Infrastructure Bonds 2015-16 Series III
IDBI Bank's Q3 results on February 12, 2016
IDBI Bank Ltd has informed BSE that a meeting of t
Go long in IDBI Bank; sell JSPL, Bata India: Chandan Taparia
Chandan Taparia of Anand Rathi Securities recommen
IDBI Bank to raise Rs 3,771 cr through QIP route
"Board of Directors of the bank has approved revis
Govt to bring in more banking reforms soon: Jaitley
Exclusive: Just how bad the bank NPA problem is
The third quarter results of banking companies hav